| Revenue growth | Revenue +31.9% YoY, +15.1% QoQ; no one-time items cited. |
|---|---|
| Margins | EBITDA margin ~14.5% vs 15% in Q1 and 9.3% in Q2 FY26. |
| Order book | Strong order book cited; no value or peer comparison disclosed. |
| Demand visibility | CDMO about 60-day order visibility; domestic branded seen near IPM growth. |
| Management confidence | Over-optimistic: repeated 'strong' and 'healthy'; no numeric guidance. |
Growth
CDMO revenue +38.6% YoY on volume growth above 20%. EBITDA margin about 14.5%, down from 15% in Q1.
Outlook
Badi phase one (6 billion tablets) fully operational by Q1 FY28. European supplies from FY28. No hard growth numbers given.
Risks
Zambia revenue slips to Q1 FY28 after Q4 dispatch. API still loses about ₹5 Cr a quarter. Domestic branded growth stays near 8%.
Earnings Call Transcript filed with BSE, NSE: AKUMS. Summary written with AI assistance from the document.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹751.50
- Market cap
- ₹11,828 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 32.5×Sector 37.9×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Limited has fully utilized its IPO proceeds totaling Rs. 680 Crore as of September 30, 2026. Consequently, further monitoring agency reports are no longer required.
- Value
- ₹680.0 Cr
Akums Drugs & Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27: revenue INR 1,342 cr (+31.9% YoY), EBITDA INR 195 cr (14.5% margin), PAT INR 115 cr (+168.3% YoY). CDMO-led growth; API losses narrowing.
Akums Drugs & Pharmaceuticals Results Update
Akums reported Q2 FY27 revenue of ₹1,342 crore, up 31.9%, and PAT of ₹115 crore, up 168%. The release is a press update with highlights, not the full results statement.
Akums Drugs & Pharmaceuticals Q2 FY27 Results: Net Profit ₹114.6 Cr, Up 168.4% YoY
Akums Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹1,342 Cr (+31.9% YoY) and net profit of ₹114.6 Cr (+168.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹114.6 Cr · +168.4% YoY
Akums Drugs & Pharmaceuticals Management Change
Akums Drugs announced the resignation of Mr. Sunil Jaiswal, SVP R&D and Senior Management Personnel, effective 31 October 2026. The resignation was submitted on 5 August 2026 citing family commitments.
Akums Drugs & Pharmaceuticals Board Meeting Date
Akums Drugs intimated that its Board meeting is scheduled for 2 November 2026 to consider un-audited Q1 and H1 FY27 results. No financial figures or decisions have been announced yet.